Advertisement

Pharmaceutisch weekblad

, Volume 1, Issue 1, pp 33–42 | Cite as

Metabolisme van geneesmiddelen — algemene aspecten en enkele nieuwe ontwikkelingen

  • J. Noordhoek
Voordrachten
  • 77 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatuur

  1. Andreasen, P.B., L. Ranek, B. E. Statland enN. Tygstrup (1974) Clearance of antipyrine-dependence of quantitative liver function,Europ. J. Clin. Invest. 4, 129.CrossRefPubMedGoogle Scholar
  2. Branch, R. A., J. A. James enA. E. Read (1976a) The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease,Clin. Pharmacol. Therap. 20, 81; (1976b) A study of factors influencing drug disposition in chronic liver disease using the model drug (+)-propranolol,Brit. J. Clin. Pharmacol. 3, 243.CrossRefGoogle Scholar
  3. Brown, B. R., enI. G. Sipes (1977) Biotransformation and hepatotoxicity of halothane,Biochem. Pharmacol. 26, 2091.CrossRefPubMedGoogle Scholar
  4. Brunk, S. F. enM. Delle (1974) Morphine metabolism in man,Clin. Pharmacol. Therap. 16, 51.CrossRefGoogle Scholar
  5. Burns, J. J. (1971) Application of metabolic and disposition studies in development and evaluation of drugs, in:Fundamentals of drug metabolism and drug disposition (Eds.B. N. Ladu, H. G. Mandel enE. L. Way). The Williams and Wilkins Cy., 340.Google Scholar
  6. Chhabra, R. S., R. J. Pohl enJ. R. Fouts (1974) A comparative study of xenobiotic-metabolizing enzymes in liver and intestine in various animal species,Drug Metab. Disp. 2, 443.Google Scholar
  7. Crooks, J., K. O'Malley enI. H. Stevenson (1976) Pharmacokinetics in the elderly,Clin. Pharmacokin. 1, 280.CrossRefGoogle Scholar
  8. Conney, A. H., E. J. Pantuck, R. Kuntzmann, A. Kappas, K. E. Anderson enA. P. Alvarez (1977) Nutrition and chemical biotransformation in man,Clin. Pharmacol. Therap. 22, 707.CrossRefGoogle Scholar
  9. Conolly, M. E., D. S. Davies, C. T. Dollery, C. D. Morgan, J. W. Paterson enM. Sandler (1972) Metabolism of isoprenaline in dog and man,Brit. J. Pharmacol. 46, 458.CrossRefGoogle Scholar
  10. Davies, D. S., C. F. George, E. Blackwell, M. E. Conolly enC. T. Dollery (1974) Metabolism of terbutaline in dog and man,Brit. J. Clin. Pharmacol 1, 129.CrossRefGoogle Scholar
  11. Depierre, J. W., enL. Ernster (1978) The metabolism of polycyclic hydrocarbons and its relationship to cancer,Biochim. Biophys. Acta 473, 149.PubMedGoogle Scholar
  12. Dutton, G. J. (1978) Developmental aspects of drug conjugation with special reference to glucuronidation,Ann. Rev. Pharmacol. Toxicol. 18, 17.CrossRefGoogle Scholar
  13. Dybing, E., S. D. Nelson, J. R. Mitchell, H. A. Sasame enJ. R. Gillette (1977) Oxidation of alpha-methyldopa and other catechols by cytochromep-450-generated superoxide anion: possible mechanism of methyldopa hepatitis,Molec. Pharmacol. 12, 911.Google Scholar
  14. Ellis, E. F., R. Koysooko enG. Levy (1976) Pharmacokinetics of theophylline in children with asthma,Pediatrics 58, 542.PubMedGoogle Scholar
  15. Evans, M., L. O. Boréus enV. Lönroth (1977) First-pass metabolism of oral pentazocine in man,Clin. Pharmacol. Therap. 22, 888.CrossRefGoogle Scholar
  16. Forrest, J. A. H., P. Roscoe, L. F. Prescott enI. H. Stevenson (1974) Abnormal drug metabolism after barbiturate and paracetamol overdosage,Brit. Med. J. (4), 742.CrossRefGoogle Scholar
  17. Hook, J. B., enW. R. Hewitt (1977) Development of mechanisms for drug excretion,Am. J. Med. 62, 497.CrossRefPubMedGoogle Scholar
  18. Hunter, J., enL. F. Chasseaud (1976) Clinical aspects of microsomal enzyme induction, In:Progress in drug metabolism, Vol. 2 (Eds.J. W. Bridges enL. F. Chasseaud). John Wiley & Sons, Londen, 129.Google Scholar
  19. Johnsson, G., enC. G. Regårdh (1976) Clinical pharmacokinetics ofΒ-adrenoceptor blocking drugs,Clin. Pharmacokin. 1, 233.CrossRefGoogle Scholar
  20. Jusko, W. J. (1978) Role of tabacco smoking in pharmacokinetics,J. Pharmacokin. Biopharm. 6, 7.CrossRefGoogle Scholar
  21. Kalow, W. (1962)Pharmacogenetics: Heredity and the response to drugs. Saunders, Philadelphia.Google Scholar
  22. Kalow, W., enT. Inaba (1976) Genetic factors in hepatic drug oxidation. In:Progress in liver disease, Vol. 5 (Eds.H. Popper enF. Schaffner). Grune and Stratton, New York - San Francisco - Londen, 246.Google Scholar
  23. Kato, R. (1977) Drug metabolism under pathological and abnormal physiological states in animals and man,Xenobiotica 7, 25.CrossRefPubMedGoogle Scholar
  24. Klotz, U., G. R. Avant, A. Hoyumpa, S. Schenker enG. R. Wilkinson (1975) The effect of age and liver disease on the disposition and elimination of diazepam in adult man,J. Clin. Invest. 55, 347.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Kutt, H., M. Wolk, R. Scherman enF. Mcdowell (1964) Insufficient parahydroxylation as a cause of diphenyl-hydantoin toxicity,Neurology 14, 542.CrossRefPubMedGoogle Scholar
  26. Lake, B. G., R. Hopkins, J. Chakraborte, J. W. Bridges enD. V. Parke (1973) The influence of some hepatic enzyme inducers and inhibitors on extrahepatic drug metabolism,Drug Metab. Disp. 1, 342.Google Scholar
  27. Levine, W. G. (1978) Biliary excretion of drugs and other xenobiotics,Ann. Rev. Pharmacol. 18, 81.CrossRefGoogle Scholar
  28. Litterst, C. L., E. G. Mimnaugh, R. L. Reagan enT. E. Gram (1974) Comparison of in vitro drug metabolism by lung, liver and kidney of several common laboratory species,Drug. Metab. Disp. 3, 259.Google Scholar
  29. Lunde, P. M., K. Frisland enV. Hausteen (1977) Disease and acetylation polymorphism,Clin. Pharmacokin. 2, 182.CrossRefGoogle Scholar
  30. Mailman, R. B., G. T. Bartholmus, K. Muse enE. Hodgson (1977) Multiplicity of hepatic cytochrome P-450 in intact microsomes,Gen. Pharmacol. 8, 275.CrossRefPubMedGoogle Scholar
  31. Menguy, R., L. Desbaillets, Y. F. Masters enS. Okabe (1972) Evidence for a sex-linked difference in aspirin metabolism,Nature 239, 102.CrossRefPubMedGoogle Scholar
  32. Mitchell, J. R., enD. J. Jollow (1975) Metabolic activation of drugs to toxic substances,Gastroenterology 68, 392.PubMedGoogle Scholar
  33. Mitchell, J. R., e.a. (1975) Increased incidence of isoniazide hepatitis in rapid acetylators: Possible relation to hydrazine metabolites,Clin. Pharmacol. Therap. 18, 70.CrossRefGoogle Scholar
  34. Mitchell, J. R., S. D. Nelson, S. S. Thorgeirsson, R. J. Mcmurtry enE. Dybing (1976) Metabolic activation. Biochemical basis for many drug-induced liver injuries, In:Progress in Liver Disease, Vol. 5 (Eds.H. Popper enF. Schaffner). Grune and Stratton, New York - San Francisco - Londen, 259.Google Scholar
  35. Mitchell, J. R., R. Mcmurtry, C. N. Statham enS. D. Nelson (1977) Molecular basis for several drug-induced nephropaties,Am. J. Med. 62, 513.CrossRefGoogle Scholar
  36. Neims, A. H., M. Warner, P. M. Loughnan enJ. V. Aranda (1976) Developmental aspects of the hepatic cytochromep-450 monooxygenase system,Ann. Rev. Pharmacol. Toxicol. 16, 427.CrossRefGoogle Scholar
  37. Nies, A. S., enD. G. Shand (1975) Clinical pharmacology of propranolol,Circulation 52, 6.CrossRefPubMedGoogle Scholar
  38. Noordhoek, J., J. H. P. Wilson, F. Liem enE. M. Savenijechapel (1975) Biological half-life and clearance of phenazone in patients with liver disease,Pharm. Weekblad 110, 1305.Google Scholar
  39. O'Malley, K., J. Crooks, E. Duke enI. H. Stevenson (1971) Effect of age and sex on human drug metabolism,Brit. Med. J. (3), 607.CrossRefPubMedPubMedCentralGoogle Scholar
  40. Pelkonen, O., E. H. Kaltiala, T. K. I. Larmi enN. T. Kärki (1974) Cytochromep-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes,Chem.-Biol. Int. 9, 20.CrossRefGoogle Scholar
  41. Pessayre, D., M. Bentata, C. Degott, O., Nouel, J. P. Miguet, B. Rueff enJ. P. Benhamon (1977) Isoniazid-rifampin fulminant hepatitis,Gastroenterology 72, 284.PubMedGoogle Scholar
  42. Quinn, G. P., J. Axelrod enB. B. Brodie (1958) Species, strain and sex differences in metabolism of hexobarbitone, amidopyrine, antipyrine and aniline,Biochem. Pharmacol. 1, 152.CrossRefGoogle Scholar
  43. Reidenberg, M. M. (1977) Obesity and fasting effects on drug metabolism and drug action in man,Clin. Pharmacol. Therap. 22, 729.CrossRefGoogle Scholar
  44. Remmer, H. (1970) Role of liver in drug metabolism,Am. J. Med. 49, 617.CrossRefPubMedGoogle Scholar
  45. Rowland, M., P. D. Thomson, A. Guichard enK. L. Melmon (1971) Disposition kinetics of lidocaine in normal subjects,Ann N. Y. Acad. Sci. 179, 383.CrossRefPubMedGoogle Scholar
  46. Sato, R., Y. Atsuta, Y. Imai, S. Taniguchi enK. Okuda (1977) Hepatic mitochondrial cytochromep-450: Isolation and functional characterization,Proc. Natl. Acad. Sci. 74, 5477.CrossRefPubMedPubMedCentralGoogle Scholar
  47. Scheline, R. R. (1973) Metabolism of foreign compounds by gastrointestinal microorganisms,Pharmacol. Rev. 25, 451.PubMedGoogle Scholar
  48. Schoene, B., R. A. Fleischmann, H. Remmer enH. F. Von Oldershausen (1972) Determination of drug metabolizing enzymes in needle biopsis of human liver,Europ. J. Clin. Pharmacol. 4, 65.CrossRefGoogle Scholar
  49. Sotaniemi, E. A., R. O. Pelkonen, R. O. Mokka, R. Huttunen enE. Viljakainen (1977a) Impairment of drug metabolism in patients with liver cancer,Europ, J. Clin. Invest. 7, 269.CrossRefGoogle Scholar
  50. Sotaniemi, E. A., O. T. Hokkanen, J. T. Ahokas, R. O. Pelkonen enJ. Ahlqvist (1977b) Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage,Europ. J. Clin. Pharmacol. 12, 429.CrossRefGoogle Scholar
  51. Svensmark, O., enF. Buchthal (1964) Diphenylhydantoin and phenobarbital. Serum levels in children,Am. J. Dis. Child. 108, 82.CrossRefPubMedGoogle Scholar
  52. Vesell, E. S. (1973) Advances in pharmacogenetics,Progr. Med. Genet. 9, 291.Google Scholar
  53. Vesell, E. S., enJ. G. Page (1969) Genetic control of phenobarbital-induced shortening of plasma antipyrine half-lives in man,J. Clin. Invest. 48, 2202.CrossRefPubMedGoogle Scholar
  54. Von Bahr, C., G. Alvan, M. Lind, B. Melström enF. Sjöqvist (1974) First-pass effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man,Acta Pharm. Suec. 11, 649.PubMedGoogle Scholar
  55. Walker, C. H. (1978) Species differences in microsomal monooxygenase activity and their relationship to biological half-lives,Drug Metab. Rev. 7, 295.CrossRefPubMedGoogle Scholar
  56. Welch, R. M., A. H. Conney enJ. J. Burns (1966) The metabolism of acetophenitidine andN-acetyl-p-aminophenol in the cat,Biochem. Pharmacol. 15, 521.CrossRefPubMedGoogle Scholar
  57. Wilkinson, G. R., enS. Schenker (1975) Drug disposition and liver disease,Drug Metab. Rev. 4, 139.CrossRefPubMedGoogle Scholar
  58. Wilkinson, G. R., enD. G. Shand (1975) A physiological approach to hepatic drug clearance,Clin. Pharmacol. Therap. 18, 377.CrossRefGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1979

Authors and Affiliations

  • J. Noordhoek
    • 1
  1. 1.Afdeling FarmacologieMedische Faculteit Erasmus UniversiteitRotterdam

Personalised recommendations